Healthcare & Life Sciences

Sirius Therapeutics

aliveseries-b
series-b
Stage
1
Investors

About

Sirius Therapeutics develops RNA interference (RNAi) therapeutics focused on cardiovascular and chronic diseases, including novel siRNA drugs aimed at reducing cardiovascular risks.

Explore Sirius Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.